✦ LIBER ✦

Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] Trials)

✍ Scribed by Emmanouil S. Brilakis; James A. de Lemos; Christopher P. Cannon; Stephen D. Wiviott; Sabina A. Murphy; David A. Morrow; Marc S. Sabatine; Subhash Banerjee; Michael A. Blazing; Robert M. Califf; Eugene Braunwald

Book ID: 113444915
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 268 KB
Volume: 102
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2008.04.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of statin dose on incidence of at

Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) and Aggrastat to Zocor (A to Z) trials

✍ Dalton S. McLean; Shmuel Ravid; Michael Blazing; Bernard Gersh; Amy Shui; Christ 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Effect of Intensive Lipid-Lowering Thera

Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 Trials)

✍ Sabina A. Murphy; Christopher P. Cannon; Stephen D. Wiviott; James A. de Lemos; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 256 KB

Improved outcome after acute coronary sy

Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial

✍ Jean Rouleau 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 319 KB

Seasonal Variation in Lipids in Patients

Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)

✍ Patricia Tung; Stephen D. Wiviott; Christopher P. Cannon; Sabina A. Murphy; Caro 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 428 KB

Assessment of adiponectin and the risk o

Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22)

✍ Sean R. Wilson; Marc S. Sabatine; Stephen D. Wiviott; Kausik K. Ray; James A. De 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 278 KB